Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

9 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 1 test: 1 consistent, 0 inconsistent, 1 via agent-written checks.

3 copyedit issues flagged: mostly consistency, clarity.

Checked 35 references: 33 verified — 1 unresolved, 1 not checked.

1 data/code link checked; 0 live.

The manuscript is conceptually and methodologically strong but requires a few critical fixes before submission: add a data availability statement, include a regulatory compliance statement, and identify statistical software. These are straightforward additions that should be made before submitting to a journal.

1. 1.
   HIGHdata code

   Add a data availability statement in the Methods section specifying how de-identified patient-level data can be accessed (e.g., by reasonable request to the ALLG, or through a repository like Vivli or clinicalstudydatarequest.com).

   ICMJE and most journals require a data availability statement for clinical trials; its absence is likely to result in a mandatory revision request.
2. 2.
   HIGHethics

   Add a sentence to the Methods (Ethics section) stating that the trial was conducted in accordance with the Declaration of Helsinki and/or ICH-GCP guidelines.

   This is a standard requirement for human clinical trials and is missing from the current manuscript.
3. 3.
   HIGHreporting

   Identify the statistical software (e.g., SAS version 9.4, R version 4.2, Stata 17) used for all analyses in the Statistical Analysis section.

   Reproducibility requires naming the software and version used; this is a common and easy fix.
4. 4.
   MEDIUMreporting

   Reference the CONSORT reporting checklist in the Methods and ensure a CONSORT flow diagram is included (Figure 1 appears to show patient flow but should be explicitly labeled as CONSORT).

   Journals endorse CONSORT for RCTs; its absence is a reporting transparency gap.
5. 5.
   MEDIUMstatistics

   Report exact p-values for the primary endpoint (e.g., p=0.00003 rather than p<0.0001) and for secondary endpoints where appropriate, noting any multiplicity adjustment.

   Threshold-only p-values ('p<0.0001') are less informative than exact values; this is a reporting best practice.
6. 6.
   MEDIUMcopyedit

   Revise the Table 2 footnote to clarify that the 'five patients' who did not proceed to transplant are accounted for: 1 death and 4 event-free patients not transplanted.

   The copyedit flagged this as a consistency issue that could confuse readers.
7. 7.
   MEDIUMcopyedit

   Specify a target range or typical dose for cyclosporin (instead of 'as per institutional practice') or state that the dose was per institutional guidelines and provide a reference if the guidelines are published.

   Reproducibility is enhanced by a more precise dosing description; the current phrase is vague.
8. 8.
   MEDIUMcopyedit

   Clarify whether the neutrophil engraftment percentages (94.1% vs 89.4%) refer to all randomized patients or only those who received a transplant.

   The denominator is ambiguous and could affect interpretation of these rates.
9. 9.
   LOWreporting

   Consider adding a brief justification for the open-label design in the Methods, noting any measures taken to minimize bias (e.g., blinded outcome assessment for GVHD).

   Addressing this known limitation strengthens transparency and reviewer confidence.
10. 10.
    LOWreporting

    Describe the randomization method in more detail, e.g., 'computer-generated random sequence with permuted blocks, stratified by age and conditioning intensity'.

    A fully described randomization method is expected for a phase 3 trial to allow assessment of allocation concealment.
11. 11.
    LOWother

    Verify the reference flagged as 'not_found_in_registry' (Phase III study comparing methotrexate and tacrolimus...) and correct or replace it if it cannot be found.

    A reference that cannot be located in any registry may indicate a fabrication signal; ensure it exists and is correctly cited.